gliclazide has been researched along with Cognition Disorders in 1 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Galan, BE | 1 |
| Zoungas, S | 1 |
| Chalmers, J | 1 |
| Anderson, C | 1 |
| Dufouil, C | 1 |
| Pillai, A | 1 |
| Cooper, M | 1 |
| Grobbee, DE | 1 |
| Hackett, M | 1 |
| Hamet, P | 1 |
| Heller, SR | 1 |
| Lisheng, L | 1 |
| MacMahon, S | 1 |
| Mancia, G | 1 |
| Neal, B | 1 |
| Pan, CY | 1 |
| Patel, A | 1 |
| Poulter, N | 1 |
| Travert, F | 1 |
| Woodward, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925] | Phase 3 | 11,140 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for gliclazide and Cognition Disorders
| Article | Year |
|---|---|
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Topics: Aged; Antihypertensive Agents; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Diabetic A | 2009 |